United States

Developed Europe

Developed Rest of World

Emerging Markets

Total Internetional

Revenue by Geography

Revenue segments as reported by the company.

Primary Care

Specialty Care

Oncology

Pfizer CentreOne

Vaccines

Hospital

Internal Medicine

Rare Disease

Inflammation & Immunology

Pfizer Ignite

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, informational and administrative expenses

Research and development expenses

Amortization of intangible assets

Restructuring charges and certain acquisition-related costs

Other (income)/deductions

Acquired in-process research and development expenses

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Pfizer

Sildenafil is a medication used to treat erectile dysfunction and pulmonary arterial hypertension. It is sold as the brand name Viagra among others.

Viagra

Atorvastatin is a member of the medication class known as statins, which are used primarily as a lipid-lowering agent and for prevention of events associated with cardiovascular disease. Like all statins, atorvastatin works by inhibiting HMG-CoA reductase, an enzyme found in liver tissue that plays a key role in production of cholesterol in the body. It is marketed under the trade name Lipitor among others

Lipitor

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Pfizer exceeds $100B in revenue, eyes growth amid challenges

Pfizer's exceptional 2022 performance sets the stage for continued success in 2023.
Strategic investments in R&D and new product launches drive revenue growth expectations.
Challenges include transitioning from emergency status and revenue decline from COVID-related products.
Opportunities lie in increased adoption of combo vaccines and business development goals.

Pfizer reports solid Q1 results, eyes growth through innovation

Pfizer's Q1 performance was strong, driven by revenue growth and patient reach.
The company faces challenges in COVID franchise transition and stock performance.
Strategic acquisitions, new product launches, and market monitoring offer growth opportunities.
Pfizer's focus on innovation, trustworthiness, and commercial efficiency underpin its future success.

Pfizer reports Q2 growth amidst COVID uncertainties and therapeutic optimism

Pfizer's Q2 performance reflects growth in non-COVID revenues, strategic acquisitions, and a focus on new product launches. Challenges include uncertainties in revenue forecasts and operational adjustments post-acquisitions. Opportunities lie in therapeutic advancements and the potential of mRNA flu vaccines.

Pfizer reports strong Q3 performance, eyes growth in non-COVID products

Pfizer's Q3 performance showcased resilience in non-COVID product revenue growth, offsetting COVID-related declines. The company's strategic focus on global health impact and innovative acquisitions positions it for future growth. Challenges in the COVID product segment persist, but Pfizer remains optimistic about opportunities in new product launches and cancer treatment advancements.

Pfizer reports solid 2023 performance, eyes growth and cost savings

Pfizer's 2023 performance was strong despite challenges, with a focus on oncology, R&D, and cost savings. The company aims for revenue growth in 2024, emphasizing shareholder value and strategic priorities.

Pfizer reports robust Q1 earnings, eyes international growth and pipeline

Pfizer's Q1 2024 performance showcased strong revenue figures and strategic focus on non-COVID products and oncology, underlining the company's resilience and growth potential.
While facing challenges in adult market contraction and gross margin issues, Pfizer's strengths in pipeline innovation, product performance, and international market growth position it well for the future.
The company's opportunities lie in continued international expansion, consumer engagement initiatives, and upcoming pipeline advancements, signaling a path for sustained growth and innovation.

Pfizer reports strong Q2 earnings, raises guidance amid leadership changes

Pfizer's Q2 2024 earnings call reflects a robust performance, marked by revenue growth, leadership changes, and enhanced guidance. The company's strategic focus on oncology, vaccines, and product differentiation positions it for continued success. Challenges include maintaining market share post-generics and managing growth expectations for VYNDAQEL.

Pfizer reports robust Q3 earnings, eyes international market growth

Pfizer's Q3 earnings call highlighted strong performance, pipeline advancements, and a focus on shareholder value creation. Challenges include addressing the impact of IRA and maintaining growth in specific product lines. Opportunities lie in international market expansion and continued pipeline innovation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Younger children between 5 and 11 years old could start getting the Pfizer-BioNTech coronavirus vaccine as soon as early November.

The FDA's expert panel just gave a thumbs-up for Pfizer's COVID-19 vaccine in younger children, clearing the path for authorization in a matter of days

The FDA typically follows the opinions of this panel, which is recommending the authorization of Pfizer's vaccine for children between the ages of 5 and 11.

FDA Advisory Committee Recommends Authorizing Pfizer's Covid Vaccine For Kids Ages 5 To 11

BioNTech SE

The FDA's decision to allow mix-and-match boosters shakes up the COVID-19 vaccine market.

Why Pfizer and BioNTech Will Be Bigger Winners Than Moderna With Mix-and-Match Boosters

Here we highlight some ETFs with high exposure to Pfizer (PFE) that can gain from the encouraging update in the coronavirus vaccine.

Will Pfizer ETFs Gain on Positive COVID-19 Booster Dose Data?

Merck

Pfizer has achieved tremendous success with its COVID-19 vaccine: Comirnaty. It continues to be the leading mRNA vaccine worldwide.

Merck Vs. Pfizer: Which Healthcare Stock Is The Better Buy?

Apple

Alphabet

Kimberly-Clark

Moderna

Microsoft

Tech Giants to Report Earnings This Week

SPDR S&P 500 ETF Trust

The Dow is +25 points, the S&P 500 +5 and the tech-heavy Nasdaq, which houses the FAANG stocks, is +45 points at this hour.

Big Week for FAANG, Economic Reads

These are Insider's biggest healthcare stories for October 25.

The FDA is set to review Pfizer's coronavirus vaccine for kids 5- to 11-years old

A Food and Drug Administration advisory committee is set to meet Tuesday to discuss and then recommend whether the benefits outweigh the risks of BioNTech SE BNTX, -2.80% and Pfizer Inc.'s PFE, +0.70% COVID-19 vaccine in children between the ages of 5 and 11 years old. The FDA is not required to follow the advice of the committee but often does.

FDA committee to discuss BioNTech/Pfizer's COVID-19 shot in children 5 to 11

FOX Business takes a look at the upcoming events that are likely to move financial markets in the coming days.

Big Tech earnings, Pfizer COVID-19 booster shot meeting, inflation data top week ahead

Clorox

Costco

Intel

Main Street Capital

Realty Income Corp

Texas Instruments

We provide a summary of upcoming ex-dividend dates in a quick reference table. The table includes relevant data and key statistics as well as the next payout and pay date.

Upcoming Ex-Dividend Dates: October 26-November 8, 2021

Johnson & Johnson

More than 47 million Pfizer vaccine recipients who received both shots at least six months ago became eligible for a booster Friday.

Covid vaccine boosters are now available. Here's who's eligible for Pfizer, Moderna and J&J's shots

Benefits of giving the Pfizer/BioNTech COVID vaccine to 5 to 11-year-olds clearly outweigh the risks, according to a US drug watchdog.

Benefits of giving Pfizer jab to 5-11-year-olds 'outweigh the risks'

Pfizer (PFE) and BioNTech announce promising data from a late-stage study evaluating the booster dose of their COVID-19 vaccine, Comirnaty.

Pfizer's (PFE) Comirnaty Booster Dose Achieves 95.6% Efficacy

American Express

Snap

V.F.

Not only good Q3 numbers, but Covid vaccine news and hope for an infrastructure passage are keeping bullish sentiment in the market.

Reasons for Optimism: Q3 Earnings, Infrastructure

Kid-size doses of Pfizer's COVID-19 vaccine appear safe and nearly 91% effective at preventing symptomatic infections in 5- to 11-year-olds, according to study details released Friday as the U.S. considers opening vaccinations to that age group.

Pfizer says COVID-19 vaccine is more than 90% effective in 5- to 11-year-olds

The latest data comes as the FDA enters the final stages of reviewing Pfizer's application to offer its shot to 5- to 11-year-olds.

The Pfizer-BioNTech COVID-19 vaccine is 91% effective in 5- to 11-year-olds, new study results show

The drugmaker said its vaccine is highly effective at preventing against symptomatic infection for children between the ages of 5 and 11.

Pfizer Says Its Covid Vaccine Is 91% Effective At Preventing Infection For Young Kids

Pfizer was strong before Covid-19 hit, but now it's on steroids. The valuation of PFE stock doesn't reflect the opportunity that lies ahead.

Pfizer is a Clear Covid-19 Winner. Is That Enough?

PFE stock is rallying now thanks to a number of catalysts, including its Covid vaccine, but it still needs to face one major obstacle. The post Pfizer Is Recovering As Its Covid Vaccine for Children Nears Approval appeared first on InvestorPlace.

Pfizer Is Recovering As Its Covid Vaccine for Children Nears Approval

Pfizer Inc (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) announced topline results from a Phase 3 trial evaluating the efficacy and safety of a 30-µg booster dose of its COVID-19 vaccine. Related:   Pfizer/BioNTech COVID-19 Boosters For Seniors, Certain Vulnerable Adults Coming Soon - CDC Panel Recommends.

Pfizer-BioNTech's COVID-19 Booster Study Shows Robust Efficacy

It's been almost a year since Pfizer published incredibly strong efficacy data from its phase 3 Covid-19 vaccine trials, setting the stage for one of the largest inoculation drives in history. Our theme of Covid-19 Vaccine Stocks has outperformed meaningfully since then, rising by about 115%.

A Year Since Pfizer's Big Breakthrough, Are Vaccine Stocks Still Worth Investing In?

A 30-microgram booster dose showed a relative vaccine efficacy of 95.6% in individuals who had previously received the Pfizer/BioNTech primary two-dose series, the companies announced.

Pfizer/BioNTech COVID-19 booster 95.6% effective against disease: study

The preliminary result comes from the first large clinical trial on Covid-19 booster shots conducted when the delta variant was the prevalent strain.

Pfizer Says Its Booster Shot Shows 95.6% Efficacy Against Covid-19

The Centers for Disease Control and Prevention's (CDC) Advisory Committee on Immunization Practices (ACIP) voted to recommend Pfizer Inc's (NYSE: PFE) Prevnar 20 pneumococcal vaccine for routine use. The CDC's Advisory Committee has also voted to recommend vaccination either with a sequential regimen of Merck & Co Inc's (NYSE: PFE) Vaxneuvance followed by Pneumovax 23 or with a single dose 20-valent pneumococcal conjugate vaccine.

News for Pfizer Stock (PFE)